Put a spi(ri)n on things

There have been previous studies showing the benefit of aspirin as an anti-cancer agent, particularly for colorectal adenomas. This study from the Lancet looks at its use in preventing colorectal cancer itself in those at higher risk (carriers of Lynch syndrome).

861 patients altogether, randomly assigned to either aspirin or placebo, followed up for over 4 years. The overall hazard ratio was 0.63 in favour of asporin, with the numbers only getting stronger with longer follow up. There was no increase in adverse events either during intervention.

Important to note the dose of aspirin here – 600mg daily, for at least 2 years – but the mechanism and concept is certainly interesting. Check it out over here.

source | The Lancet
image | Chaval Brasil
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s